secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENSAR, Inc. (LNSR)
CIK:        0001320350
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0001564590-22-008409
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENSAR Q4 2021 revenue $11.2M (+35% YoY); full-year revenue up 31% to $34.2M; net loss narrows
--------------------------------------------------------------------------------

- Q4 revenue $11.2M vs $8.3M YoY; full-year revenue $34.2M (+31% vs 2020).
- Net loss $3.9M ($0.41 per share) vs $6.8M ($0.78) in Q4 2020; loss narrowed.
- Procedure volume up 37% in Q4 and 35% for full year 2021.
- ALLY Adaptive Cataract Treatment System 510(k) submitted and accepted for FDA substantive review.
- Cash of $31.6M with only $0.7M used in Q4; commercial launch of ALLY expected in 2022 subject to FDA clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1320350/000156459022008409/0001564590-22-008409-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1320350/000156459022008409/lnsr-8k_20220303.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-008409

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer